(Q34412092)

2 August 2017

1 reference

title

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy (English)

1 reference

2 August 2017

1

Holgate ST

1 reference

2 August 2017

Djukanović R

2

1 reference

2 August 2017

Casale T

series ordinal

3

1 reference

2 August 2017

Bousquet J

series ordinal

4

1 reference

2 August 2017

publication date

1 April 2005

1 reference

Clinical & Experimental Allergy

2 August 2017

published in

1 reference

2 August 2017

volume

35

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

408-416

1 reference

The role of dendritic cells in immune regulation and allergic airway inflammation.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Omalizumab improves asthma-related quality of life in children with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

The effect of omalizumab on nasal allergic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

The role of T lymphocytes in the pathogenesis of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Increased expression of high affinity IgE (FcepsilonRI) receptor-alpha chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Human recombinant interleukin 4 induces Fc epsilon R2/CD23 on normal human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Risk factors and costs associated with an asthma attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Links between rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02191.X

10.1111/J.1365-2222.2005.02191.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference